Neuropathic pain is a complex chronic condition characterized by various sensory, cognitive, and affective symptoms. A large percentage of patients with neuropathic pain are also afflicted with depression and anxiety disorders, a pattern that is also seen in animal models. Furthermore, clinical and preclinical studies indicate that chronic pain corresponds with adaptations in several brain networks involved in mood, motivation, and reward. Chronic stress is also a major risk factor for depression. We investigated whether chronic pain and stress affect similar molecular mechanisms and whether chronic pain can affect gene expression patterns that are involved in depression. Using two mouse models of neuropathic pain and depression [spared nerve injury (SNI) and chronic unpredictable stress (CUS)], we performed next-generation RNA sequencing and pathway analysis to monitor changes in gene expression in the nucleus accumbens (NAc), the medial prefrontal cortex (mPFC), and the periaqueductal gray (PAG). In addition to finding unique transcriptome profiles across these regions, we identified a substantial number of signaling pathway-associated genes with similar changes in expression in both SNI and CUS mice. Many of these genes have been implicated in depression, anxiety, and chronic pain in patients. Our study provides a resource of the changes in gene expression induced by long-term neuropathic pain in three distinct brain regions and reveals molecular connections between pain and chronic stress.
INTRODUCTION
Chronic pain is a debilitating condition affecting more than 100 million Americans (1), with more than half showing comorbid depression and anxiety (2) (3) (4) . Several recent studies using rodent models of chronic pain reveal adaptations in mood-and stress-related brain regions, with corresponding effects in nociceptive behaviors and motivation-, anxiety-, and depression-related behaviors, as well as analgesic efficacy (5) (6) (7) (8) (9) (10) (11) . Moreover, neuroimaging studies from chronic pain patients show altered activity in the nucleus accumbens (NAc) and the medial prefrontal cortex (mPFC) (12) (13) (14) , two brain regions that are part of the brain reward center and have documented roles in the pathophysiology of depression (15) . The NAc displays connections with multiple brain regions, including the ventral tegmental area, amygdala, thalamus, and mPFC, and shows altered activity in murine models of stress-induced depression as well as upon noxious stimulation or relief from pain (5, (16) (17) (18) (19) (20) (21) . Notably, both chronic stress (22) and nerve injury (23) result in altered dendritic spine morphology in the mPFC, whereas optogenetic activation of mPFC-NAc projections modulates sensory and affective symptoms of neuropathic pain (6) and induces resilience to chronic social defeat stress (24) . Accordingly, several studies report plasticity-related alterations in the prefrontal cortex (PFC) of rodents in models of neuropathic pain (21, (25) (26) (27) .
The periaqueductal gray (PAG) plays a critical role in descending modulation of pain (28, 29) and mediates opioid analgesia (28, 30) . Recent findings have also shown that chronic pain corresponds with greater functional connections between the ventromedial PFC and PAG in humans (31) , and robust mPFC-PAG projections have been confirmed in rodents (32) . Rodent models of chronic pain and stress induce plasticity within the PAG (33) (34) (35) , and PAG activation modulates anxiety-like behaviors (36, 37) .
Although chronic stress and chronic pain conditions have been shown to correspond with plasticity-related changes in the mPFC, NAc, and PAG, few studies have investigated network-wide cellular and molecular adaptations within these areas in response to long-term pain. Critically, several studies using rodent chronic pain models report that depression-like behaviors do not appear until at least 6 weeks after injury (7, (38) (39) (40) , and thus, an understanding of the molecular adaptations in mood-related brain regions at these later time points is of paramount importance. Here, we used the murine spared nerve injury (SNI) model of neuropathic pain (41, 42) , along with nextgeneration RNA sequencing (RNA-seq) to monitor gene expression changes in the mPFC, NAc, and PAG tissue of adult mice 2.5 months after nerve injury. Our data indicate that distinct transcriptional profiles emerge across these brain regions in correspondence with longterm neuropathic pain but show some overlapping effects in signaling pathways and biological functions. We demonstrate a significant overlap between differentially expressed genes identified in this data set and genes implicated in depression, anxiety, and pain from human postmortem or mutant mouse studies. Last, we confirm the correspondence of genes to depression by comparing the expression pattern in a distinct mouse model of depression, namely, chronic unpredictable stress (CUS) (43) .
of mechanical allodynia, as indicated by decreases in mechanical thresholds in the von Frey test that had persisted for 2 months (Fig. 1B) . In addition, 2 months after surgery, we used the elevated plus maze (EPM) and open-field (OF) tests to assess anxiety-related exploratory behavior (45) . SNI mice showed significantly less exploration of the open arms in the EPM (sham, 12 ± 2.5%; SNI, 4.2 ± 0.7%) (Fig. 1C) and spent significantly less time in the center area of the OF as compared to sham mice (sham, 12.4 ± 2.3%; SNI, 5.9 ± 1.7%) (Fig. 1D) . We next assessed whether SNI affected depression-like behaviors through the sucrose consumption and forced swim tests (FSTs) (46) . At the 9-week time point, the SNI mice showed a significantly reduced preference for sucrose consumption (sham, 77 ± 1.4%; SNI, 58 ± 3.9%) (Fig. 1E ) and also showed significantly longer duration of immobility in the FST (sham, 128.14 ± 10.6 s; SNI, 167.29 ± 6.5 s) (Fig. 1F) . A 60-min assessment of locomotor activity showed no difference between the groups at 2 months ( fig. S1 ). These data show that SNI induces persistent nociceptive sensitization and long-term enhancements in anxiety-and depression-like behaviors.
Long-term neuropathic pain corresponds with distinct altered gene expression patterns in the mPFC, NAc, and PAG We next investigated whether long-term SNI was associated with changes in gene expression in brain regions known to be involved in anxiety and depression, and thus, we performed next-generation RNA-seq on mPFC, NAc, and PAG tissue collected from adult male mice 2.5 months after SNI or sham surgeries. Our RNA-seq design maximized the trade-off between biological replicates and sequencing depth to obtain high statistical power (47) and sequenced six biological replicates per brain region, per group ( fig. S2 ). RNA-seq read alignment and differential analysis were performed by using the voom limma and TopHat packages. We achieved an average mapping depth of 58.9 million ± 20.8 million reads, with a mapping rate of 92 ± 0.33%. We quantified gene expression levels in each brain region and compared levels from the sham and SNI groups to determine SNI-induced differentially expressed genes. Longterm SNI corresponded with robust changes in gene expression and distinct patterns of up-regulated versus down-regulated genes (mPFC: up-regulated, 179; down-regulated, 204; NAc: up-regulated, 135; down-regulated, 691; PAG: up-regulated, 6539; down-regulated, 1225).
We next characterized whether differentially expressed genes showed patterns of coexpression across the three brain regions by using the rank-rank hypergeometric overlap (RRHO) test (48, 49) . This test characterizes the patterns and significance of overlap between gene expression profiles by comparing ranked lists of differentially expressed genes in the mPFC, NAc, and PAG. Although some coregulation can be seen across all three brain regions, the NAc and PAG show a remarkably robust pattern of co-up-regulated genes ( Fig. 2A) . Accordingly, comparisons of the gene expression patterns between the NAc and PAG show stronger Spearman rank correlation coefficient values (rho = 0.547), as compared to comparisons between the NAc and mPFC (rho = 0.332) and between the mPFC and PAG (rho = 0.195). A total of 3594 genes were found to be up-regulated by SNI in both the NAc and PAG brain regions of mice (Fig. 2B) . We examined the gene ontology of these specific genes and found that several biological functions are implicated by these co-up-regulated genes, including intracellular signaling cascade, regulation of biosynthesis, transcription, phosphorylation, and metabolic processes. Furthermore, histone deacetylase 4 (HDAC4), HDAC5, and HDAC7 were found to be implicated in 40% of the biological processes represented by the co-up-regulated genes. A protein-protein interaction map of the genes implicated in the regulation of biosynthesis showed that HDAC5, in Fifty percent of mechanical thresholds of mechanical allodynia were determined using von Frey filaments before surgery (baseline) and every 2 weeks thereafter. n = 16 mice per group, F 1, 120 = 155, P < 0.001; twoway analysis of variance (ANOVA) and Holm-Sidak adjustment for multiple comparisons. 14d, 14 days. (C to F) Anxiety-like behaviors assessed in an EPM test (C) (n = 9 mice per group, t 16 = 3.03, P = 0.008; unpaired t test), in an OF test (D) (n = 9 mice per group, t 16 = 2.24, P = 0.04; unpaired t test), for sucrose consumption (E) (n = 9 mice per group, t 16 = 4.62, P < 0.001; unpaired t test), and in an FST (F) (n = 9, t 16 = −3.15, P = 0.004; unpaired t test). Data in (B) to (F) are means ± SEM. *P < 0.05. particular, interacted with a robust number of proteins coded by genes in this gene ontology group (Fig. 2C) , and several studies have linked its expression with stress-induced depression and antidepressant effects (7, 50, 51) . In a separate group of mice, using real-time quantitative polymerase chain reaction (qPCR), we confirmed that HDAC5 is upregulated in the NAc [sham, 1.00 ± 0.14 fold change (FC); SNI, 3.98 ± 1.03 FC] and PAG (sham, 0.98 ± 0.06 FC; SNI, 1.15 ± 0.04 FC) 2.5 months after injury (Fig. 2D ).
HDAC5 plays a critical role in neuropathic pain states Given the implications of HDAC5 in depression-related behaviors and antidepressant effects, we next sought to determine whether a genetic mutant lacking the expression of HDAC5 [HDAC5 knockout (KO)] showed altered behavioral effects to long-term SNI. We exposed HDAC5 KO and HDAC5 wild-type (WT) mice to SNI and found both groups displayed robust mechanical allodynia in response to SNI (Fig. 3A) , with no differences detected between HDAC5 KO and HDAC5 WT in either the SNI-or the sham-treated group. In contrast, emotion-related behavior differed significantly in response to long-term SNI, with HDAC5 KO mice displaying significantly reduced SNI-induced depressionand anxiety-like behaviors compared to HDAC5 WT mice. Nine weeks after surgery, sham-treated HDAC5 WT and HDAC5 KO showed similar sucrose preference values (HDAC5 WT, 75 ± 3.4%; HDAC5 KO, 72 ± 3.2%), whereas SNI-treated HDAC5 WT mice showed significantly lower sucrose preference values than HDAC5 KO mice (HDAC5 WT, 49 ± 5.9%; HDAC5 KO, 63 ± 2.4%) (Fig. 3B) . In a similar manner, HDAC5 KO mice also showed resiliency to SNI-induced increases in anxiety-like behaviors. In the EPM, although sham-treated HDAC5 WT and HDAC5 KO mice showed equal levels of exploratory behavior in the open arm (HDAC5 WT, 13.41 ± 2.5%; HDAC5 KO, 13.49 ± 0.8%), 
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long-term SNI reduced exploratory behavior only in HDAC5 WT mice, whereas HDAC5 KO mice showed significantly greater levels of exploratory time in the open arm compared to HDAC5 WT (HDAC5 WT, 5.03 ± 1.2%; HDAC5 KO, 14.97 ± 4.1%) (Fig. 3C) . Likewise in the OF, SNI-treated HDAC5 KO mice showed significantly more exploration in the center area compared to HDAC5 WT mice (HDAC5 WT, 5.11 ± 1.6%; HDAC5 KO, 10.86 ± 1.9%) (Fig. 3D) , whereas groups exposed to sham surgery showed similar levels (HDAC5 WT, 8.56 ± 1.7%; HDAC5 KO, 9.78 ± 1.5%). Antidepressants are commonly prescribed for chronic pain symptoms, and previous work indicates that HDAC5 modulates antidepressant effects in chronic stress models (50) . Therefore, we next tested the possibility that mice lacking HDAC5 may respond differently to chronic treatment with duloxetine, a serotonin and norepinephrine reuptake inhibitor that has antiallodynic properties (52) . Three weeks after SNI surgery, HDAC5 WT and HDAC5 KO mice showed similar levels of mechanical allodynia as evidenced by very low 50% mechanical thresholds (HDAC5 WT, 0.37 ± 0.10 g; HDAC5 KO, 0.43 ± 0.09 g). We then commenced chronic duloxetine treatment (5 mg/kg every 12 hours) and tested their nociceptive responses to von Frey filaments every 5 days. Remarkably, HDAC5 KO mice showed a significantly faster and stronger antiallodynic response to chronic duloxetine that was evident as early as after 10 days of treatment (Fig. 3E) . A two-way repeated-measures ANOVA revealed a significant difference between groups. Together, these data indicate that HDAC5 modulates the emotional effects induced by long-term SNI and is involved in the antiallodynic effects of antidepressants.
Gene expression patterns in the mPFC, NAc, and PAG undergo robust FC after long-term neuropathic pain We next sought to identify the genes that undergo the most robust changes in expression as a consequence of chronic neuropathic pain and applied a strict threshold to generate lists of genes that showed a differentially expressed FC of 1.50 or greater and only included genes with P values of 0.05 or less (table S1). With these cutoffs, hierarchical clustering revealed distinct overall patterns in gene expression profiles across the three brain regions (Fig. 4A) . The patterns of up-regulated versus down-regulated genes varied across all three brain regions (mPFC: up-regulated genes, 36; down-regulated, 53; NAc: up-regulated genes, 13; down-regulated genes, 110; PAG: upregulated genes, 724; down-regulated genes, 71) (Fig. 4B) . We next used VennPlex (53) to group differentially expressed genes from all three brain regions to assess the commonalities and differences based on their corresponding expression values. Remarkably, little overlap in regulated genes was observed, with only one up-regulated gene (Capn11) and one down-regulated gene (Cyp2e1) in common across all three brain regions (Fig. 4C ).
Gene expression patterns in the mPFC, NAc, and PAG reflect common biological functions and signaling pathways We next sought to characterize the effects SNI-induced changes in gene expression may have on biological networks and neural function. We used the Ingenuity Pathway Analysis (IPA), allowing us to compare our differentially expressed data set with more than 1,480,000 experimentally observed interactions between molecules (54). Using the Fisher's exact test, network scores are generated on the basis of the number of molecules they contain, with higher scores representing lower probabilities of finding the observed genes by chance alone. The total number of network-eligible differentially expressed genes from our data set varied across the three brain regions, with the PAG displaying the largest amount (mPFC, 16; NAc, 21; PAG, 238). Table 1 displays the top biological networks that contain more than four differentially expressed genes. As expected from the distinct pattern of differentially expressed genes observed, the mPFC, NAc, and PAG showed unique molecular networks. Nevertheless, the top network represented in all three brain regions involved a network implicated to affect behavior, and both the NAc and PAG had a significant overrepresentation of genes corresponding to neurological disease. We next performed IPA's causal network analysis that identifies upstream molecules experimentally shown to control the expression of the differentially expressed genes from our data set. This analysis recognizes regulators known to exert a direct relationship as well as molecules through which a master regulator modulates gene expression. Activation states (activated or inhibited) are determined from Measurements were made using von Frey filaments. No significant difference was observed between groups at any time point (F 1, 324 = 1.11, P = 0.355), and there was no interaction between genotype, type of surgery, and time (F 8, 324 = 1.36, P = 0.214). n = 10 mice per group. (B to E) SNI-treated HDAC5 WT and HDAC5KO mice were monitored in the sucrose preference test (B) (n = 10 mice per group, t 18 = −2.2, P = 0.041; unpaired t test), in the EPM test (C) (n = 10 mice per group, t 18 = −2.3, P = 0.033; unpaired t test), in the OF test (D) (n = 10 mice per group, t 18 = −2.3, P = 0.035; unpaired t test), and in the von Frey assay (E) after chronic duloxetine (5 mg/kg every 12 hours) (n = 7 mice per group, F 1, 48 = 9.0, P = 0.01; two-way ANOVA and HolmSidak adjustment for multiple comparisons). Data are means ± SEM. *P < 0.05 z scores that indicate whether there is a significant match between the predicted and observed gene expression pattern; only z scores ≥2 or ≤−2 are considered to be significant predictors of activity. As with the biological networks, distinct master and participating regulators were observed across the three brain regions, but only molecules from the mPFC and PAG showed relative expression levels that could be considered statistically significant ( Table 2) . We next used IPA to assess the overlap between differentially expressed genes in the mPFC, NAc, and PAG and gene sets known to be involved in specific signaling pathways. Despite the stringent cutoffs, a vast amount of signaling pathways were implicated in each brain region (mPFC, 78; NAc, 142; PAG, 189). Nineteen canonical signaling pathways showed significant levels of differentially expressed genes in at least two brain regions, including five pathways that were affected in all three brain regions: cyclic adenosine 3′,5′-monophosphate (cAMP)-mediated, G protein (heterotrimeric GTP-binding protein)-coupled receptor (GPCR), insulin-like growth factor 1 (IGF-1), pregnenolone biosynthesis, and glucocorticoid receptor signaling pathways (Fig. 5A) . Thus, although SNI promotes unique adaptations in gene expression in the mPFC, NAc, and PAG, some of these adaptations appear to affect signal transduction networks that are similarly regulated in all three regions examined.
Our data, as well as several other studies, demonstrate that SNI not only produces long-term nociceptive sensitization but also promotes anxiety-and depression-like behaviors. We next took advantage of IPA's extensive database to determine the extent of overlap between the differentially expressed genes in our study and genes identified in the literature as being implicated in pain, anxiety, or depression. Remarkably, a large subset of differentially expressed genes across all three brain regions overlapped with IPA-identified molecules implicated in the literature in depression-, anxiety-, and pain-like conditions ( Fig. 5B and Table 3 ). A total of 39 genes were identified, including 8 genes that had been implicated in depression, 9 in anxiety, 5 in pain, 4 in depression and anxiety, 2 in pain and depression, 2 in pain and anxiety, and 9 in all three conditions. However, together with our behavioral findings, our data indicate that all 39 of these genes correspond with neuropathic pain-induced depression and anxiety. Our findings extend beyond 39 genes and implicate 89 genes in the mPFC, 123 in the NAc, and 795 in the PAG. To validate the SNI-induced differential expression patterns of key genes, we next performed qPCR on a variety of differentially expressed genes implicated in the 19 common pathways and in the overlap with the literature (Fig. 6A ). Multiple genes that have been previously implicated in anxiodepressive and nociceptive states were validated, including Cyp2e1, Btg2, Cyr61, Tph2, Ccl3, Fos, Sgk1, Dusp1, and Slc17a8. In addition, several previously unreported genes were also validated, including Capn11, Oacyl, Mt1, and Vgf. Because the protein product of Capn11 (calpain 11) belongs to a large family of calciumdependent cysteine proteases (55), we also assessed the mRNA levels of the two most prototypical calpains, calpain 1 (Capn1) and calpain 2 (Capn2), which showed no SNI-induced regulation. Because increased Capn11 expression was confirmed in all three brain regions, we next sought to determine whether inhibition of calpain proteins can rescue SNIinduced mechanical allodynia and enhanced anxiety-and depressionlike behaviors. We exposed adult (8-week-old) male C57BL/6 mice to SNI and confirmed the presence of mechanical allodynia for 60 days, after which they were separated into two groups: one receiving systemic injections of the calpain inhibitor MDL 28170 (3 mg/kg daily) and the other receiving daily saline injections (Fig. 6B ). We performed von Frey assessments of mechanical thresholds 1 and 2 weeks after drug treatment and found that MDL 28170 increased mechanical thresholds, indicating that it reduced mechanical allodynia. A two-way repeated-measures ANOVA revealed a significant interaction between drug treatment and time, whereas only mice receiving MDL 28170 Table 1 . Top biological networks corresponding to differentially expressed genes in the mPFC, NAc, and PAG. Networks are composed of molecules and differentially expressed genes experimentally observed to interact with each other and scored relative to all molecules they are known to be connected to. Using a Fisher's exact test, network scores are generated on the basis of the number of molecules they contain, with higher scores representing lower probabilities of finding the observed genes in a randomly selected network by chance alone. Genes in boldface indicate SNI-induced differentially expressed genes in mPFC, NAc, or PAG. Only networks that include more than one differentially expressed gene are presented. Renal and urological system development and function, reproductive system development and function, and cardiovascular disease 9 BAIAP2, CASC5, CASK, CASKIN1, CCND1, CDC6, Crip2, DLG2, EPOR, FAM83D, FOSB, GDNF, GRIN2B, HDAC1, HTR1A, ITPKA, L-dopa, LIN7B, LMNA, LMNB2, LZTS3, MIB2, NT5E, NTRK3, PCLO, PHOX2B, SATB1, SHANK3, SNCA, SNCB, TH, TLE1, TPPP3, VAMP2, YIF1B
15
Cell death and survival, behavior, and cell-to-cell signaling and interaction
10
Acetylcholine, ACHE, ACTA1, AP2M1, APP, BACE1, DPYSL2, ELN, FBXO2, FGF2, FLNA, FZR1, GIPC1, GNA12, GNAS, GRIN1, ITGB1, MAP1LC3A, MAP2K4, MDK, Mt1, MT-CO1, NF1, NGFR, NRP1, PAWR, RAC1, RHOA, RTN4R, SLC5A7, SOD1, SPHK2, TFEB, TIMM23B, TOMM40
14
Nervous system development and function, cellular assembly and organization, and cellular development continued on next page Cell death and survival, tissue morphology, and nervous system development and function
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showed increased thresholds after 2 weeks of daily injections (Fig. 6C) . Compared with daily saline injections, mice receiving daily MDL 28170 showed similar low levels of exploratory behavior in the EPM (Fig. 6D ) and similar levels of immobility in the FST (Fig. 6E ). These data indicate that chronic calpain inhibition can reduce SNI-induced nociceptive sensitization after 2 months of neuropathic pain but cannot rescue enhanced expression of anxiety-and depression-related behaviors.
Differentially expressed genes in the mPFC, NAc, and PAG under neuropathic pain states are also regulated by CUS To determine whether SNI-induced differentially expressed genes are linked to anxiodepressive behaviors, we tested whether chronic stress alters the expression of genes shown to be regulated by SNI. We used the CUS model, which has been shown to induce depression-like behaviors in mice (56, 57) . In our protocol, we did not use any stimuli that promote injury, inflammation, or nociception (see Materials and Methods and Fig. 7A ). Four weeks of CUS promoted depression-like states, as indicated by significantly increased latencies to eat in the novelty-suppressed feeding (NSF) test (baseline, 73.8 ± 6.8 s; CUS, 134.4 ± 21.6 s) (Fig. 7B ) and significantly reduced sucrose preference (baseline, 87.3 ± 0.6%; CUS, 77.7 ± 1.7%) (Fig. 7C) . NSF has been shown to reflect changes in anxiety-and depression-like behaviors (58) . Remarkably, multiple genes were regulated by both CUS and SNI. Specifically, three genes that were regulated by SNI in the mPFC [Btg2 (B cell translocation gene 2; antiproliferative), Cyr61 (cysteine-rich protein), and Dusp1 (dual-specificity phosphatase 1)] showed similar patterns of regulation in the mPFC after CUS (Btg2, 0.57 ± 0.09 FC; Cyr61, 0.46 ± 0.06 FC; Dusp1, 0.50 ± 0.04 FC) (Fig. 7D) . In the NAc, Btg2, Capn11 (calpain 11), cytokine Ccl3 (also known as macrophage inflammatory protein 1a), and FOS (FBJ osteosarcoma oncogene) were also regulated in the same direction by SNI and CUS (Btg2, 0.74 ± 0.09 FC; Capn11, 2.71 ± 0.68 FC; Ccl3, 1.45 ± 0.08 FC; Fos, 0.53 ± 0.13 FC) (Fig.  5E ). In the PAG, Sgk1 (serum glucocorticoid-regulated kinase), the vesicular glutamate transporter Slc17a8 (solute carrier family 17 member 8; also known as Vglut3), and Capn11 were also similarly regulated by SNI and CUS (Sgk1, 1.38 ± 0.13 FC; Slc17a8, 0.37 ± 0.08 FC; Capn11, 1.28 ± 0.05 FC) (Fig. 7F ). These data demonstrate that several genes in the mPFC, NAc, and PAG are regulated in a similar manner by neuropathic pain states and CUS.
DISCUSSION
Using next-generation RNA-seq, we present the first report of gene expression adaptations in three mood-associated brain regions in response to long-term neuropathic pain in mice. We show that SNI enhanced anxiety-and depression-like behaviors 2 months after nerve injury, which corresponded with distinct differentially expressed gene patterns, biological networks, and upstream regulators, in all three brain regions. Despite these differences, common biological functions and signaling pathways were identified. Our findings also indicate that neuropathic pain states promote several gene expression adaptations that are also observed in models of depression.
Our data indicate that HDAC5 is regulated by long-term neuropathic pain states in the NAc and PAG. Using RRHO, we identified robust co-up-regulation of multiple genes in the NAc and PAG in correspondence with long-term SNI. Through gene ontology analysis, we found that HDAC5, which encodes for an enzyme (HDAC5) known to promote the stability of compact chromatin forms, was implicated in several 
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biological processes overrepresented by co-up-regulated genes in the NAc and PAG. We further found that genetic deletion of HDAC5 attenuates SNI-induced anxiety-and depression-like phenotypes. Previous studies have documented the role of HDAC5 in modulation of antidepressant drug efficacy in models of stress or neuropathic pain (7, 50) . In line with these findings, our study suggests that HDAC5 is a negative modulator of serotonin and norepinephrine reuptake inhibitor (SNRI) actions and points to HDAC5 inhibitors as potential targets for the treatment of neuropathic pain. Unexpectedly, HDAC5 expression in the NAc and PAG was not captured by our subsequent analysis using the stringent FC cutoff of 1.50. However, it is worth noting that within the PAG, HDAC5 expression was increased in the SNI group by an FC of 1.48, just barely missing the 1.50 cutoff. Despite stark differences in predicted upstream regulators, we observed that one gene (Capn11) was up-regulated and one gene (Cyp2e1) was down-regulated in all three brain regions of mice exposed to SNI. Cyp2e1 is a cytochrome p450 family member linked to ethanol and nicotine intake (59) (60) (61) (62) that is known to be regulated by inflammatory cytokines (63) (64) (65) . Future studies will need to clarify the role of Cyp2e1 in reward mechanisms under chronic pain states and its role in sensory and affective symptoms of pain conditions. Similar to the network-wide Cyp2e1 reduction, all three brain regions showed upregulated Capn11 expression; this gene codes for the protein calpain 11, an intracellular, calcium-dependent cysteine protease (55). Calpain 11 is most similar to the classical calpains (1, 2), containing all three typical domains in the large subunit. Cortical expression of Capn11 mRNA is observed in mice, mainly in astrocytes, but is also expressed in neurons and microglia (66) .
Calpain substrates in neurons include synaptic proteins such as membrane receptors, cytoskeletal proteins, postsynaptic density proteins, and intracellular mediators involved in synaptic function (67, 68) , indicating that neuropathic pain-induced calpain activity may mediate various plasticity-related processes. Although nociceptioninduced changes in calpain 11 have not been investigated, calpain inhibitors that prevent the action of all calpains are used in most investigations, and findings include reports stating that calpains mediate AMPA receptor subtype editing (69) and glycine-mediated increases in dendritic spine density of cultured hippocampal neurons (70) . Furthermore, our data showing that a nonselective calpain inhibitor has antiallodynic effects are in accordance with two recent rat studies that have shown that 14 days of systemic calpain inhibition reduces cancer bone pain (71) and nociceptive sensitization induced by diabetic neuropathy (72) .
Our findings also suggest that the patterns of differentially expressed genes induced by SNI are indicative of altered activity of various signal transduction pathways, including glucocorticoid receptor-, cAMP-, and GPCR-mediated signaling. Glucocorticoids have been established to be involved in the effects of chronic stress in humans (73) (74) (75) and rodents (76) (77) (78) . Our finding that SNI alters glucocorticoid signaling also agrees with studies showing that stress-induced increases in corticosterone potentiate SNI-induced allodynia in mice (44) . Similarly, we report that SNI-induced differential expression of genes is implicated in cAMP-mediated signaling, in accordance with studies linking perturbations of cAMP signaling pathways to depression-like (79) and chronic pain-like states (80) (81) (82) (83) (84) (85) . The pregnenolone biosynthesis signaling pathway was also affected in all three brain regions in response to SNI. Decreased neurosteroid biosynthesis has been implicated as a possible contributor to the development of anxiety and depressive disorders (86, 87) . Attention has turned to allopregnanolone (88) , which acts as a potent positive allosteric modulator of g-aminobutyric acid type A (GABA A ) receptors (89) , has anxiolytic effects in rodents, and promotes the efficacy of fluoxetine (90) (91) (92) . Pregnenolone biosynthesis deficiencies resulting in altered GABA A modulation are supported by recent findings that GABA A signaling in the PAG is altered by persistent inflammation in rats (93) .
Among the 19 pathways that showed altered activation in at least two brain regions, several have been previously implicated in anxiety or depression. For example, we demonstrate changes in IGF-1 signaling and several proinflammatory and anti-inflammatory interleukinmediated pathways, in accordance with observations that stressful experiences affect the function of inflammatory molecules (94) . Moreover, alterations in inflammatory pathways promote changes in brain circuitry involved in mood, stress, and pain (44, 95, 96) .
Numerous neuroimaging studies show that in humans, pain is associated with activity in the NAc, mPFC, and PAG (13, 14, 28) . These regions display robust reciprocal connections (11) and form a network capable of exerting top-down regulation of nociceptive input (28, 29) . In particular, the PAG plays a prominent role in descending modulation of pain through its projections to the nucleus raphe magnus (28, 29) and can excert either facilitatory or inhibitory effects on spinal regions. Notably, mPFC neurons project to the PAG (32), and therefore, gene expression changes in this brain region may affect PAG activity and modulation of pain transmission. PFC projections to NAc have also been shown to modulate sensory and affective symptoms of neuropathic pain (6) . In addition, the NAc is connected to several brain regions that modulate nociceptive perception and mood, including the PFC, the amygdala, and the hippocampus (6, 15, 24, 31, 32) . Gene expression changes in mood-related networks can affect the perception of nociceptive information as well as the responsiveness to antidepressant medications (7). We have shown that disruption of HDAC5 expression, which is found to be up-regulated in the NAc and PAG in SNI mice, affects behavioral responses to SNRI treatment.
Various SNI-induced differentially expressed genes identified in our study have been previously reported to be implicated in depression-, anxiety-, and pain-like conditions. Tph2 was robustly reduced in the mPFC, and a decrease in tryptophan hydroxylase 2 (TPH2) abundance is being considered as a trait marker for depression (97) (98) (99) . Likewise, we found that SNI caused a robust decrease of Dusp1 in the mPFC. DUSP1 controls the expression of several inflammationinduced genes, including IL-6, IL-10, Ccl3, Ccl4, and Cxcl2 (100). Overexpression of Dusp1 in the rat spinal cord prevents neuropathic pain (101), whereas mice with genetic deletion of Dusp1 are resilient to stress-induced depression (102), suggesting distinct roles for Dusp1 in spinal versus supraspinal sites. Some of the differentially expressed genes identified showed opposite expression patterns from those previously reported on depression and anxiety. For example, Btg2 mRNA is enhanced in the neocortex of mice in response to acute immobilization stress (103), whereas we found it to be decreased in the mPFC and NAc of SNI and CUS mice. Because the up-regulation of Btg2 was observed in a model of acute stress, it remains to be investigated how chronic stress conditions affect the expression of this gene in mPFC and NAc. Similarly, we found SNI reduced the expression of Cyr61 and Dusp1 in the mPFC, but previous studies have linked increases in the expression of these genes in the neocortex and hippocampus to anxiety and depression (102, 103) . These differences may underlie brain region-and cell type-specific effects of stress and nerve injury on Cyr61 and Dusp1 expression or may suggest that these genes play distinct roles in neuropathic pain versus chronic stress states.
Moreover, we observed decreases in Fos expression in the NAc of SNI and CUS mice, and although the antidepressants imipramine (104) and milnacipran (10) enhance c-Fos expression in the PFC of rats, homozygous Fos KO mice show reduced anxiety-like behaviors (105) . Nevertheless, these observations highlight the value of network-wide analysis and the potential detrimental effects the disruptions in normal gene expression (be it enhanced or decreased) may exert on normal emotional function.
Here, we found that SNI causes anxiodepressive symptoms and differentially expressed genes in the mPFC, NAc, and PAG similar to mice exposed to CUS, a distinct stress model validated to induce depression in mice. Most of these genes have been observed to be involved in plasticity-related processes, and their altered expression may reflect adapted brain states in chronic pain and mood disorders. Within the mPFC, Btg2 expression was reduced, and previous findings have shown Btg2 involvement in neurite outgrowth (106) and histone H4 arginine methylation and acetylation processes (107) . Similarly, Cyr61 expression was also reduced in SNI and CUS groups of mice, and its activity is critical for dendritic growth in hippocampal neurons (108) . Within the NAc, Ccl3 was enhanced in the SNI and CUS groups, and its protein product, the proinflammatory cytokine Ccl3, is known to enhance inflammatory responses within the central nervous system and increase Ca 2+ signaling in cultured neurons (109, 110) . Notably, spinal cord injury leads to Ccl3 up-regulation in the hippocampus (111) , and its expression is positively correlated with depression (112, 113) . NAc samples of SNI and CUS mice also showed similar decreases in Fos, and the link between activity-dependent Fos expression, synaptic plasticity, and learning and memory has been well documented (114) (115) (116) (117) . Likewise, multiple differentially expressed genes in the PAG of SNI and CUS mice have been linked with anxiety and depression. The expression of Sgk1, up-regulated in both SNI and CUS mice, is up-regulated in the corpus callosum (118) and hippocampus (119) by chronic stress, and mRNA amounts of Sgk1 are increased in peripheral blood samples from patients with major depression (119) . Similarly, genetic deletion of Slc17a8 (Vglut3), the expression of which was reduced in the PAG of both the SNI and CUS groups in our study, enhances anxiety-like behaviors in adult mice that correspond with decreases in serotonin [5-hydroxytryptamine (5-HT)]-mediated neurotransmission in the raphe nuclei (120) . Some SNI-induced gene expression patterns were not observed in the CUS model, however, including changes in the expression of Tph2 and Capn11 in the mPFC, Oacyl and Cyp2e1 in the NAc, and Mt1 and Vgf in the PAG. These differences may rely on the models or time points selected or on the influences of input from nociceptive neurons in the examined brain regions. Recent work characterizing long-term neuropathic pain-induced methylation changes in the PFC and peripheral T cells of rats showed that SNI-induced gene expression patterns correlate with the severity of nociceptive sensitization (25) . Future work should determine whether similar correlations can be observed with anxiodepressive symptom severity and whether gene expression patterns can be predictive of anxiodepressive symptom development in models of neuropathic pain.
An understanding of the genes and signal transduction networks regulated by long-term neuropathic pain in mood-regulating networks will help determine whether drugs targeting nociceptive transmission and perception also affect long-term adaptations that lead to depression or whether adjunct medications need to be used. Several types of antidepressants, such as tricyclic antidepressants and selective serotoninnorepinephrine reuptake inhibitors, target both spinal pathways and mood-regulating networks and are among the top prescribed medications Fig. 7 . SNI and chronic stress cause similar gene expression patterns in the mPFC, NAc, and PAG. (A) CUS experimental timeline. CUS was administered for four consecutive weeks, after which behavior was assessed or animals were sacrificed and brains were extracted for further analysis. (B) In the NSF test, CUS increased latencies to eat (n = 11, t 20 = −2.7, P = 0.015; unpaired t tests). (C) CUS decreased sucrose consumption rates (n = 11, t 20 = −5.3, P < 0.001; unpaired t tests). (D) Genes regulated by CUS and SNI in the mPFC: Btg2 (n = 7, t 12 = 2.8, P = 0.017; unpaired t tests), Cyr61 (n = 7 mice per group, t 12 = 7.3, P < 0.001; unpaired t tests), and Dusp1 (n = 6, t 10 = 4.4 P < 0.001; unpaired t tests). (E) Genes regulated by CUS and SNI in the NAc: Btg2 (n = 7, t 12 = 2.8, P = 0.042; unpaired t tests), Capn11 (n = 9, t 16 = −2.5, P = 0.024; unpaired t tests), Ccl3 (n = 7, t 12 = −3.65, P = 0.003; unpaired t tests), and Fos (n = 7, t 12 = 3.3 P = 0.006; unpaired t tests). (F) Genes regulated by CUS and SNI in the mouse PAG: Sgk1 (n = 7 mice per group, t 12 = −2.4, P = 0.034; unpaired t tests), Slc17a8 (n = 7, t 12 = 3.6, P = 0.004; unpaired t tests), and Capn11 (n = 7, t 12 = − 4.5 P < 0.001; unpaired t tests). Data are mean FC ± SEM. *P < 0.05.
for neuropathic pain (121) . However, unfortunately, full efficacy is only reached by a subset of patients, and their use is limited by the slow onset of action and severe adverse effects. Future studies must investigate cell type-specific adaptations in gene expression after long-term neuropathic pain and should include several other regions modulating cognition, motivation, and responses to stress. These studies are expected to provide important information on the genes and networks that need to be targeted to efficiently treat neuropathic pain.
MATERIALS AND METHODS
Animals
We used adult (8-to 9-week-old) male C57BL/6 mice purchased from The Jackson Laboratory, and HDAC5 knockout or wild-type controls bred on a C57BL/6 background and maintained in a colony at our facility. Mice were group-housed (three mice per cage) and were kept on a 12-hour light/dark cycle with food and water available ad libitum. All procedures were performed in accordance with the guidelines of the animal care committees at Icahn Medical School at Mount Sinai and approved by the Institutional Animal Care and Use Committee.
SNI model
The SNI model of neuropathic pain was performed under Avertin (2,2,2-tribromoethanol; Sigma-Aldrich) general anesthesia, as previously described (7, 41) . Briefly, skin and muscle incisions were made on the left hindleg at midthigh level, revealing the sciatic nerve and its three branches Drugs Duloxetine (Tocris) was dissolved in phosphate-buffered saline to a concentration of 0.5 mg/ml. MDL 28170 (Tocris) was first dissolved in dimethyl sulfoxide (DMSO) and then diluted before injection to the desired concentration, so that the injected solution contained 5% DMSO. Control saline injections included equal amounts of DMSO. All injections were administered intraperitoneally, alternating sides between each injection.
Behavioral analysis
Mechanical allodynia was measured through the top-down method (44) using von Frey filaments (Stoelting), with ascending forces expressed in grams (0.04 to 2.0 g). Each filament was applied five times in a row against the medial plantar surface of the hindpaw. Prolonged hindpaw withdrawal, rapid fanning, or licking induced by the filament was defined as a positive nociceptive response. The lowest gram-force eliciting positive responses in three of five repetitive stimuli was defined as the 50% withdrawal threshold. Mice were habituated to the von Frey apparatus for 1 hour on test days before analysis.
In the FST, mice were placed in individual glass cylinders (46-cm height × 18-cm diameter) containing water at room temperature (25°± 1°C) at a depth of 15 cm and were allowed to freely swim in the container for 6 min; sessions were videotaped for offline analysis. Immobility measurements were determined as time spent immobile, with the exception of a single paw flick to remain afloat. Analysis was performed by a blind observer.
To assess sucrose consumption, mice were single-housed with sucrose (1%) or water available for a period of 24 hours. Sucrose consumption was determined as total sucrose consumed divided by the total water and sucrose consumption, multiplied by 100. Bottles were rotated at 3, 6, and 12 hours to prevent side bias. Measurements were taken by a blind observer.
EPM and OF tests were performed under red light conditions, and mice were acclimatized to the room for 1 hour before testing. The EPM consisted of two open arms and two closed arms situated opposite to each other (each measuring 12 × 50 cm). The number of entries and time spent in each arm were recorded and analyzed using the Noldus EthoVision 10.1 software. For OF test, mice were allowed to freely explore the OF arena (50 × 50 × 20 cm) for 5 min. Time spent in the center versus border regions of the arena were recorded and analyzed using Noldus EthoVision 10.1. Analysis was performed by a blind observer.
Novelty-suppressed feeding NSF was performed as reported previously (45) with minor modifications. Briefly, mice were food-deprived for 24 hours prior and habituated to the testing room for 1 hour. Under red light conditions, mice were placed in a plastic chamber (50 × 50 × 20 cm) with wood chip bedding. A single pellet of regular food chow was placed in the center of the chamber. Mice were placed in the corner of the box, and latency to eat was measured, with a cutoff time of 10 min.
CUS model CUS was performed as published previously (46) with minor modifications. Briefly, groups of male C57BL/6 mice (8 weeks old) were either exposed to 4 weeks of CUS or housed under the same conditions but left undisturbed (control). All mice were given access to food and water ad libitum. The CUS protocol was based on a weekly schedule of the following stressors: overnight illumination (light on during nighttime), cage tilting (45°angle), bedding removal, wet bedding, restraint (2 hours; restraint by attaching tail on cage wall), and removal of food for 12 hours. Two different stressors were applied per day, each one during the light or dark phase cycle. The sequence of stressors applied was designed to maximize unpredictability.
RNA-seq experiments RNA-seq was performed on polyadenylated fractions of isolated RNA. Briefly, two groups of mice (SNI and sham) with six biological replicates per group were used. Bilateral punches were taken from the mPFC, NAc, and PAG, and punches were pooled from two mice per sample, so that there was a total of 12 animals per treatment group. Total RNA was isolated from pooled bilateral punches of two animals per replicate (six biological replicates per treatment group) using TRIzol (Life Technologies) according to the manufacturer's instructions. RNA was purified with RNeasy Micro Kit 50 (catalog no. 74004, Qiagen) according to the manufacturer's instructions, and Agilent 2100 Bioanalyzer confirmed that the RNA integrity numbers were >9.0. Poly-A-containing mRNA was purified by using poly-T oligo-attached magnetic beads, and the mRNA-seq library was prepared from each pooled RNA sample by using the Illumina TruSeq RNA Sample Preparation Kit v2, according to the manufacturer's protocol. RNA-seq was performed on the Illumina HiSeq 2000 machine at the Mount Sinai School of Medicine's Genomic Core facility. Fifty-base pair (bp), paired-end short reads were aligned to the mouse genome (mm10) using TopHat2. Uniquely aligned reads were counted against the GENCODE vM2 annotation using HTSeq. Differential analysis was performed using the voom limma R library, determining
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differentially expressed genes using a cutoff of P < 0.05. Gene ontology analysis was performed by using the functional annotation and clustering software tool available through the online Database for Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics Resources (version 6.7) (https://david.ncifcrf.gov/). Only terms with P < 0.05 are reported. To identify potential protein interactions between the products of the differentially expressed genes in our results, we used the STRING (version 9.1) software and database. Venn diagrams were generated by using VennPlex version 1.0.0.2 (National Institutes of Health). IPA was used to identify genes involved in depression and to determine potential activated pathways, upstream regulators, and biological functions (7).
Rank-rank hypergeometric overlap
To evaluate global gene expression profiles, the RRHO test (48, 49) was performed between two sets of brain region-specific differential gene expression comparisons. RRHO uses a threshold-free approach and ranks differentially expressed genes to determine the statistical significance of the number of overlapping genes, providing hypergeometric P values for the enrichment of overlapping genes for all possible rank pairs for both brain regions. The direction signed log 10 -transformed hypergeometric P values were corrected for multiple comparisons according to the Benjamini and Yekutieli method (48) .
Hierarchical clustering heatmaps
Variance-stabilized expression values were computed using DESeq R package. To separately visualize relative expression in each brain region, the variance-stabilized values were z-scored for each differentially expressed gene. Hierarchical clustering was performed on these genes using Euclidean distance and plotted.
Real-time qPCR qPCR was performed as reported previously (7) . Total RNA was isolated from frozen bilateral punches of single animals (NAc and PAG) or pooled two per sample (mPFC) using TRIzol (Life Technologies), according to the manufacturer's instructions, and was purified using chloroform (Sigma-Aldrich), precipitated with isopropanol (Sigma-Aldrich) and 75% ethanol (Sigma-Aldrich), and eluted in ribonuclease-free water (Life Technologies). RNA was reverse-transcribed into complementary DNA (cDNA) using qScript cDNA Synthesis Kit (Quanta Biosciences). Primers were designed to amplify regions of 50 to 250 bp (table S2) located in the genes of interest selected from the IPA analysis. All reactions run in triplicate, assessed using the DDC t method, and normalized to glyceraldehyde-3-phosphate dehydrogenase (Gapdh).
Data analysis
Results are presented as means ± SEM. Statistical analyses were performed using unpaired or paired Student's t tests, or two-way repeatedmeasures ANOVA, with post hoc adjustments for multiple comparisons using the Holm-Sidak method. For analysis of sham and SNI HDAC5 WT and HDAC5 KO von Frey measurements, we used a three-way ANOVA. In all cases, the significance threshold was set at P < 0.05.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/10/471/eaaj1549/DC1 Fig. S1 . Locomotor behavior of sham and SNI mice 2 months after surgery. Fig. S2 . Column dendrogram for all three brain regions. Table S1 . Differentially expressed genes in the mPFC, NAc, and PAG of SNI mice. Table S2 . Primers used for qPCR experiments.
